Table 3.
Treatment-emergent adverse events occurring in ≥5% of patients in either treatment group during the maintenance phase
Preferred term | Epoetin alfa-epbx n = 122 | Epoetin alfa n = 122 |
---|---|---|
Any treatment-emergent AE, n (%) | 85 (69.7) | 86 (70.5) |
Nausea | 10 (8.2) | 8 (6.6) |
Pyrexia | 8 (6.6) | 4 (3.3) |
Fall | 8 (6.6) | 3 (2.5) |
Dizziness | 3 (2.5) | 9 (7.4) |
Injection-site pain | 3 (2.5) | 8 (6.6) |
AE, adverse event.